Selenious acid
As of the edition of 20 October 2026, Selenious acid is a small molecule: marketed, first approved in 1988 (FR).
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2019
- Kind
- Small molecule
- Brand name
- Tralement
- First approved
- 7 November 1988 (FR)
- Approvals on record
- 9 in 3 regions
- Holder of the most recent approval
- American Regent; 4 holders in all
- Registered trials
- 5, 1 stopped early
- Disease areas
- Cancer; Blood and lymph; Urinary and reproductive; Heart and blood vessels; Immune system; Infections
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 2 | 1 | 0 | 1 |
| Phase 2 | 3 | 1 | 0 | 0 |
| All trials | 5 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| American Regent | Applicant | 2019 to now |